Getinge 2022 Annual Report

Getinge 2022 Annual Report Introduction Strategy Corporate Governance Annual Report Sustainability Report Other information Contents NOV DEC JAN BOARD OF DIRECTORS' WORK IN 2022 During the year, a total of 11 Board meetings were held, with an attendance rate of 100% of the members elected by the AGM. At its ordinary meetings, the Board has addressed fixed agenda items in accordance with the Board's rules of proce- dure and annual plan. Accordingly, the Board has addressed the Group's long-term objectives and strategy, risks and risk management, sustainability issues, financial plan, investment plan, annual accounts and financial reports and also adopted corporate governance documents. The Board has continuously addressed business situation and financial issues, ethics and compliance, quality issues, regulatory issues, succession plan- ning and talent development, as well as general organizational issues. During the year, the Board also addressed matters related to legal proceedings, corporate acquisitions, other investments and financing. Matters relating to the pandemic, Russia's invasion of Ukraine, the changed financial climate, supply chain challenges and external factors and how these impact the Group and the Group's adjustments to these issues, were regularly addressed and discussed. At one of its meetings, the Board met with the company's auditor without the presence of the President & CEO or any other individual from executive management. The Board also continuously evaluated the work of the President & CEO and devoted one meeting to this matter without the presence of executive management. Board and Committee meetings in 2022 Q4 Audit and Risk Committee meeting Remuneration Committee meeting Board meeting: Financial plan, strategy review Global Sales & Service, succession planning, talent development etc., risk assessment and risk management process (ERM), Ethics & Compliance Extraordinary Board meeting* Audit and Risk Committee meeting Remuneration Committee meeting Board meeting: Interim report and nine-month report (Q3), strategy review Surgical Workflows, investments, financing, acquisition agenda and legal proceedings Q3 Audit and Risk Committee meeting Audit and Risk Committee meeting Board meeting: Half-yearly report (Q2), establishment matters and in- vestments, and legal proceedings OKT SEP AUG Q4 Q3 *Extraordinary Board meetings are typically held to address specific or urgent matters related to various topics such as financial issues, disputes, corporate acquisitions and other investments. 36 JUL Q1 Q2 FEB JUN MAJ MAR APR Q1 Audit and Risk Committee meeting Remuneration Committee meeting Board meeting: Full-year report (annual accounts and Q4 report), strategy review Acute Care Therapies, AGM-related resolutions, investments and evaluation of the Board and President & CEO Board meeting: Approval of Annual Report, including Sustainability Report, and Corporate Governance Report Q2 Audit and Risk Committee meeting Board meeting: Interim report (Q1), sustainability, strategy review Life Science, quality updates, investments, financing and legal proceedings Statutory Board meeting: Election of committee members, authorized signatories, policies, etc. Extraordinary Board meeting* Board meeting: Group strategy, investments, lessons learned from the pandemic and legal proceedings and one Extraordinary Board meeting*

View entire presentation